D
Dopavision
Therapeutic company developing a digital therapeutic for myopia
About Dopavision
Dopavision is a pioneering company in the field of digital therapeutics, focusing on innovative solutions for myopia control. The company leverages smartphone technology to deliver treatments that are both effective and user-friendly. Dopavision primarily serves patients suffering from myopia, a condition characterized by nearsightedness, which is increasingly prevalent among children and adolescents. Operating within the healthcare and technology markets, Dopavision employs a business model that combines direct-to-consumer sales with partnerships in the medical community. Revenue is generated through the sale of their digital therapeutic products and potential collaborations with healthcare providers and insurance companies. The company's leadership team brings a wealth of experience from various fields, including neuroscience, vision sciences, and software management, ensuring that their products meet the highest regulatory standards. Dopavision aims to make a significant impact on global eye health by providing accessible and effective treatments for myopia.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Berlin, Germany
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 57.9/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Children, Digital Therapeutics, Tech for Patients, Hard Tech, Digital Care
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2021 | $13M | $53M | Boehringer Ingelheim Venture Fund · Novartis · Ababax Health · Seventure Partners | ↗ |
| SEED✓Equity / VC | Jun 2019 | $1.4M | $5.5M | Flying Health · Ralf Wahlsten · Boehringer Ingelheim Venture Fund | — |
Growth signals
Latest recorded traffic for Dopavision is 500 monthly website visits, down 19.4% over the last three months. Dopavision's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Boehringer Ingelheim Venture Fund
Flying Health
Ralf Wahlsten
Series A3 investors entered at this stage
Seventure Partners
Novartis
Ababax Health
Other known investors1 additional known investor
dRx Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dopavision on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dopavision’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.